Abstract: A sensor driving device can include an image sensor substrate including a fixed portion, a moving portion movable with respect to the fixed portion, and a connection portion connecting the fixed portion and the moving portion, a coil moving substrate disposed on the image sensor substrate to be movable with the moving portion of the image sensor substrate, and a coil unit disposed on the coil moving substrate. Also, the coil unit includes a plurality of coils each disposed in a plurality of first corner portions of the coil moving substrate, and the connection portion includes a plurality of bent portions that overlap each of the plurality of coils in an optical axis direction and are bent in different horizontal directions.

Abstract: The present application relates to: a compound of chemical formula 1, an isomer thereof or a pharmaceutically acceptable salt thereof; and use thereof for preventing, alleviating and/or treating inflammasome-mediated diseases and/or Gram-negative bacteria infections or diseases caused by Gram-negative bacteria, does not exhibit cell cytotoxicity, and thus is safe, and can effectively inhibit inflammasomes, thereby having the excellent effects of preventing, alleviating and/or treating these diseases.

Abstract: A substrate according to an embodiment includes an insulating layer; a first pattern portion disposed on the insulating layer; and a second pattern portion disposed on the insulating layer and spaced apart from the first pattern portion, wherein the insulating layer includes a first insulating portion including a first open region; and a second insulating portion disposed to surround an outside of the first insulating part and spaced apart from the first insulating portion with a second open region therebetween; wherein the first pattern portion includes a first lead pattern portion disposed on the first insulating portion; a second lead pattern portion disposed on the second insulating portion; and a connection pattern portion having one end connected to the first lead pattern portion and the other end connected to the second lead pattern portion, and disposed on the second open region; wherein the connection pattern portion includes a bent portion positioned on a corner of the second open region.

Abstract: A substrate according to an embodiment includes an insulating layer; a first pattern portion disposed on the insulating layer; and a second pattern portion disposed on the insulating layer and spaced apart from the first pattern portion, wherein the insulating layer includes a first insulating portion including a first open region; and a second insulating portion disposed to surround an outside of the first insulating part and spaced apart from the first insulating portion with a second open region therebetween; wherein the first pattern portion includes a first lead pattern portion disposed on the first insulating portion; a second lead pattern portion disposed on the second insulating portion; and a connection pattern portion having one end connected to the first lead pattern portion and the other end connected to the second lead pattern portion, and disposed on the second open region; wherein the connection pattern portion includes a bent portion positioned on a corner of the second open region.

Abstract: Provided are: a pharmaceutical composition, food composition, or feed composition for improving the intestinal microbial population comprising galactose, and for reducing body weight; and use thereof for preventing and/or treating and/or ameliorating obesity.

Abstract: The present invention relates to use for the prevention and/or alleviation and/or treatment of hypersensitivity immune disease, containing galactose and, more particularly, provides a pharmaceutical composition and a health functional food that comprise galactose for the prevention, amelioration and/or treatment of hypersensitivity immune disease such as atopic dermatitis.

Abstract: Compositions, systems and methods of sequencing are disclosed, where the compositions and systems include polymerase enzymes that have been genetically modified to more efficiently incorporate nucleotides including labels having a detectable properties that are released during incorporation, to augment a rate of labeled nucleotide incorporation, to augment a rate of pyrophosphate release, or to augment two or more of these properties and rates. Also disclosed are terminally labeled and dual labeled nucleotides, and click-chemistry based methods of synthesizing the same.